Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Iron Chelation Basics
In this webcast, Dr. Taher, an expert in the treatment of thalassaemia, discusses goals and strategies of iron chelation therapy, focusing on new data on myocardial iron removal and providing an update on the long-term tolerability of iron chelators. The webcast also includes a discussion of the efficacy and tolerability of treatment with high-dose (>30 mg/kg) deferasirox.
|
|
Faculty
|
|
|
Ali T. Taher, MD
Professor
Department of Internal Medicine
American University of Beirut Medical Center
Beirut, Lebanon
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Based on an understanding of the goals of iron chelation and the properties of an ideal iron chelator, individualize iron chelation therapy for transfusion-dependent patients to reduce/prevent iron overload.
- Based on recent clinical data with high-dose (>30 mg/kg) deferasirox, determine the most effective starting and maintenance doses to achieve optimal iron balance.
|
Disclosure Information
Ali T. Taher, MD, is on the speakers bureau of and on the advisory board for Novartis Pharmaceuticals Corporation.
|
|
|
|
|
|
|
